AI in a GxP Environment: What You Can and Can't Do Yet
AI is useful in pharma's non-GxP functions today and genuinely difficult inside GxP scope — not because regulators banned it, but because validation and data integrity expectations apply to AI too. A sober answer for executives who have been asked about AI by their board.
AI is straightforwardly usable in pharma today in the parts of the business that aren't GxP — document drafting, literature review, internal knowledge search, IT operations — with normal data controls. Inside GxP scope it runs into validation and data integrity expectations that most current AI tools cannot satisfy, not because regulators have banned AI, but because the rules that govern any computerized system apply to AI too, and non-deterministic systems are hard to validate in the way those rules assume.
Regulatory thinking in this area is moving quickly. This article reflects the position as of October 2026. Cite the primary documents rather than this article if you are making a decision.
See where your regulated environment actually stands.
Fifteen questions, about five minutes, scored on screen with a remediation roadmap emailed to you.
I run regulated IT environments for pharmaceutical and biotech companies. What follows is the answer I give executives who have been asked about AI by their board and need something more useful than enthusiasm or fear.
What does "GxP scope" actually mean for a software tool?
A system is in GxP scope when it creates, modifies, stores, or influences a record that supports a regulated decision. The test is what the output is used for, not what the software is called. A spreadsheet used to track a deviation is in scope; the same spreadsheet used to plan an offsite is not. A word processor used to draft an SOP is in scope; the same tool used to draft a press release is not.
This matters for AI because the same tool can be in or out of scope depending on where the output lands. A general-purpose assistant that drafts meeting notes is out of scope. The same assistant used to draft a deviation report that becomes part of the quality record is in scope — and the validation expectations that apply to any GxP system now apply to the path that output traveled. 21 CFR Part 11 sets the baseline for electronic records and signatures in this context, and its requirements do not soften because the system behind them is a language model.
Where is AI straightforwardly useful today?
Outside GxP scope, AI is already useful:
- Document drafting outside the quality system. Drafts of marketing copy, internal memos, board updates, vendor communications. These are not quality records, and a human reviews them before they go out.
- Literature review. Summarizing papers, extracting findings across a body of literature, drafting state-of-the-art summaries. The output informs a person's judgment; it does not become a record on its own.
- Meeting summarization. Transcripts, action items, decisions. Useful internally, kept out of the quality system.
- Internal knowledge search. Indexing internal documents so people can find what the company already knows.
- Code and script assistance. Drafting, reviewing, and explaining code for internal tooling. The code is reviewed and tested before it runs anything that matters.
- Vendor and contract review. Flagging clauses, comparing terms, surfacing obligations a human should read carefully.
- Forecasting. Demand, cash flow, pipeline — internal planning tools where the output informs a decision but is not the decision.
- IT operations. Log analysis, anomaly detection, draft incident summaries, and the operational work FDA investigators look at in your IT systems when they examine how you run the environment.
The data controls still apply. Where the prompts go, what the vendor retains, and whether confidential or IP-bearing material is leaving your tenant are questions you need answered before you put anything sensitive into a tool. A consumer-grade assistant that trains on your inputs is fine for a draft memo and wrong for a clinical data summary.
Why is AI in GxP environments harder to validate?
Validation assumes a system produces consistent, reproducible output for a given input. Most current AI systems do not. A large language model can return different answers to the same prompt on different days, and the model itself changes as vendors update it. That is the core difficulty: the validation framework assumes you can qualify a system and demonstrate it behaved the same way in production as it did in qualification, and a non-deterministic model makes that demonstration hard.
Beyond determinism, GxP systems need an audit trail — a record of who did what, and when. AI features that generate content inside a GxP system need to attribute the action to a person, log what the model returned, and preserve a record that an auditor can reconstruct. A feature that inserts AI-generated text into a quality record without a clear audit trail is a compliance problem regardless of whether the text is correct.
The honest statement is that these are not insurmountable problems, but they are unsolved for most general-purpose tools in most real environments. There is not yet clear guidance on how to validate a non-deterministic AI system inside GxP scope in the way you validate a LIMS or an ERP, and pretending the gap doesn't exist is how companies end up with findings they didn't see coming.
What about AI features inside systems you already use?
This is the most under-considered risk. Vendors are enabling AI features by default in platforms that already sit in GxP scope — document management, LIMS, quality systems, and productivity suites. A summarization feature switched on in a validated document management system is a change to that system. Under change control, a change to a validated system requires assessment, approval, and re-validation as needed — whether the vendor made the change or you did.
The practical implication: someone in your organization needs to be tracking vendor release notes for exactly this reason. When a vendor enables an AI feature in a GxP system, the question is not "should we use it" but "has this change been assessed and is the feature switched off until it is." Most companies are not doing this, and most vendors are not making it easy to tell what changed.
What have regulators actually said?
FDA has been publicly engaging with AI across drug development and manufacturing. The agency published a discussion paper on using AI and machine learning in drug development (May 2023, revised February 2025) and a discussion paper on AI in drug manufacturing. More recently, FDA issued guidance on the use of AI to support regulatory decision-making for drugs and biological products, which sets out a risk-based credibility assessment framework for evaluating an AI model for a particular context of use.
EMA published a reflection paper on the use of AI in the medicinal product lifecycle (July 2023), which outlines principles for AI and machine learning use across the medicines lifecycle and emphasizes a human-centric approach and compliance with existing legal requirements.
None of these documents is an approval of AI for GxP use. They are frameworks and invitations to dialogue. The FDA guidance applies to AI used to produce information supporting regulatory decision-making about safety, effectiveness, or quality — a specific and important context, not a blanket clearance. The guidance is evolving, and the position at time of writing should not be read as settled. If you are uncertain whether something is permitted, that uncertainty is legitimate — say so plainly rather than guessing.
What questions should you ask a vendor claiming AI capability?
- 1.Is the output deterministic for a given input? If not, how do they propose to validate it inside GxP scope? "It doesn't need validation" is not an acceptable answer for a system in GxP scope.
- 2.Can you produce an audit trail showing what the model returned and when? Not just the final output, but the prompt, the response, and who accepted it.
- 3.What happens to our data? Does it leave your tenant? Is it used to train the vendor's models? What is the retention period? Get this in writing.
- 4.How will you notify us before enabling a new AI feature? Not after. Before. And what is the mechanism for us to decline or disable it?
- 5.Can the feature be switched off? If the answer is no, the feature is being forced into your validated environment without your consent.
- 6.Has anyone used this in a GxP context and been inspected? Ask for specifics. "It's designed for regulated industries" is not the same as "it has been used in a GxP environment and survived an FDA inspection."
How should you govern this internally?
Most companies have AI in use already, informally, and don't know where. That is the starting condition, not a problem to be embarrassed about — but it is a problem to fix. Four things:
- 1.A written AI use policy. What is permitted, what is not, where the line between GxP and non-GxP use sits, and who approves exceptions. A one-page policy that people actually read is better than a fifty-page one they don't.
- 2.A clear line between GxP and non-GxP use. Defined, documented, and communicated. The pharmaceutical industry page covers the regulatory context that shapes this line.
- 3.A person who owns vendor release monitoring. Someone whose job it is to read the release notes for GxP-scope systems and flag AI features before they land. This is a small commitment and a large risk if it isn't done.
- 4.A simple register of where AI is in use across the business. What tool, what function, what data, who owns it, is it in GxP scope. The register does not need to be sophisticated. It needs to exist.
Where AI is usable today, and where it runs into GxP
| Use case | In GxP scope? | Practical today? | What to control |
|---|---|---|---|
| Marketing and PR drafting | No | Yes | Human review before publish |
| Literature review and summaries | No | Yes | Source verification; output informs, doesn't decide |
| Meeting summarization | No (if not a quality record) | Yes | Keep out of the quality system |
| Internal knowledge search | No | Yes | What gets indexed; data residency |
| Code and script assistance | No (internal tooling) | Yes | Code review and testing before use |
| Vendor and contract review | No | Yes | Human reads the contract, not just the summary |
| Forecasting and demand planning | No | Yes | Output informs planning; not the record |
| IT operations (log analysis) | Depends on what's logged | Yes | Whether logs are quality records |
| AI features in a validated document system | Yes | Difficult | Change control; feature off until assessed |
| Drafting SOPs and deviation reports | Yes | Difficult | Audit trail; validation; human accountability |
| Clinical data summarization for a submission | Yes | Not yet clear | No settled validation approach; proceed with caution |
| Pharmacovigilance signal detection | Yes | Emerging | Human-in-the-loop; regulatory engagement early |
The governance point
The companies that will use AI well in regulated environments are the ones that know where it's already being used. Most don't. An executive who can tell their board "we have a register, here's what's in GxP scope, here's what isn't, and here's the person who watches vendor releases" has done more than one who has bought a tool and hoped. The technology will keep changing. The discipline of knowing where you are — that is what stays useful.
Photo by Miká Heming on Unsplash.
Frequently asked questions
Don't see your question? Email info@isectra.com and we'll answer it directly.

Santiago runs regulated IT environments for pharmaceutical and biotech companies. He writes for executives who have been asked about AI by their board and need an answer that is neither hype nor alarm.
Get the next post in your inbox.
Signal, once or twice a month. No spam — just the posts worth reading.
Let's see what your IT could feel like.
A senior engineer will review your environment and respond within 24 hours. No sales script, no obligation.

